Cargando…

667. Next Generation Sequencing of Microbial Cell Free DNA in the Diagnosis and Treatment of Infectious Disease in Children: When Does the Result Justify the Cost?

BACKGROUND: Pathogen testing using next-generation sequencing of microbial cell-free DNA (NGS cfDNA) is a promising diagnostic tool to identify pathogens that might not be detected using conventional lab evaluation. Considering the cost of this test, it is important to determine when it is most usef...

Descripción completa

Detalles Bibliográficos
Autores principales: Quick, Rachel Downey, Martinez, Kelli A, Russo, Susan M, McGwier, Sarah E, Quirt, Rachel A, Hauger, Sarmistha Bhaduri, Fernandez, Mariosl, Murphey, Donald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644926/
http://dx.doi.org/10.1093/ofid/ofab466.864
_version_ 1784610199373348864
author Quick, Rachel Downey
Martinez, Kelli A
Russo, Susan M
McGwier, Sarah E
Quirt, Rachel A
Hauger, Sarmistha Bhaduri
Fernandez, Mariosl
Murphey, Donald
author_facet Quick, Rachel Downey
Martinez, Kelli A
Russo, Susan M
McGwier, Sarah E
Quirt, Rachel A
Hauger, Sarmistha Bhaduri
Fernandez, Mariosl
Murphey, Donald
author_sort Quick, Rachel Downey
collection PubMed
description BACKGROUND: Pathogen testing using next-generation sequencing of microbial cell-free DNA (NGS cfDNA) is a promising diagnostic tool to identify pathogens that might not be detected using conventional lab evaluation. Considering the cost of this test, it is important to determine when it is most useful to the plan of care (POC). Figure 1. Unit of admission among cases [Image: see text] Figure 2. Patient characteristics in cases determined to be valuable and not valuable to the plan of care (POC) [Image: see text] METHODS: In this retrospective study, we collected data from the medical charts of 50 consecutive NGS cfDNA tests in a free-standing children’s hospital. We evaluated patients for demographics, underlying conditions, diagnosis at time of testing, conventional laboratory testing and timing, medical treatment, and NGS cfDNA test results for clinical relevance or false negative results compared to conventional testing. The primary goal was to identify patients for whom the NGS cfDNA testing affected the POC. Charts were reviewed, and determinations regarding whether the result influenced the POC were confirmed by a provider. RESULTS: We were unable to differentiate patients with clinically valuable NGS cfDNA results (Fig 1 & 2). Among those with NGS cfDNA results valuable to the POC (n=22), both negative and positive testing guided POC (13 valuable negative vs. 9 diagnostic cases). In the total sample, 5 cases (10%) had a clinically relevant pathogen identified through conventional testing, but not through NGS cfDNA and 2 cases had antimicrobial resistance on culture, which is not detected by NGS cfDNA. CONCLUSION: While we did not find a specific clinical profile for NGS cfDNA use, positive results were essential to the diagnosis in 18% of cases with otherwise negative laboratory evaluation for the pathogen identified in NGS cfDNA. Negative tests affected the POC in 26% of cases by avoiding unnecessary antimicrobials in high risk immunocompromised patients and patients that presented with low-risk of infection, but unclear disease process. Caution must be exercised with reliance on this test with respect to antimicrobial resistance and risk of false negative results. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-8644926
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86449262021-12-06 667. Next Generation Sequencing of Microbial Cell Free DNA in the Diagnosis and Treatment of Infectious Disease in Children: When Does the Result Justify the Cost? Quick, Rachel Downey Martinez, Kelli A Russo, Susan M McGwier, Sarah E Quirt, Rachel A Hauger, Sarmistha Bhaduri Fernandez, Mariosl Murphey, Donald Open Forum Infect Dis Poster Abstracts BACKGROUND: Pathogen testing using next-generation sequencing of microbial cell-free DNA (NGS cfDNA) is a promising diagnostic tool to identify pathogens that might not be detected using conventional lab evaluation. Considering the cost of this test, it is important to determine when it is most useful to the plan of care (POC). Figure 1. Unit of admission among cases [Image: see text] Figure 2. Patient characteristics in cases determined to be valuable and not valuable to the plan of care (POC) [Image: see text] METHODS: In this retrospective study, we collected data from the medical charts of 50 consecutive NGS cfDNA tests in a free-standing children’s hospital. We evaluated patients for demographics, underlying conditions, diagnosis at time of testing, conventional laboratory testing and timing, medical treatment, and NGS cfDNA test results for clinical relevance or false negative results compared to conventional testing. The primary goal was to identify patients for whom the NGS cfDNA testing affected the POC. Charts were reviewed, and determinations regarding whether the result influenced the POC were confirmed by a provider. RESULTS: We were unable to differentiate patients with clinically valuable NGS cfDNA results (Fig 1 & 2). Among those with NGS cfDNA results valuable to the POC (n=22), both negative and positive testing guided POC (13 valuable negative vs. 9 diagnostic cases). In the total sample, 5 cases (10%) had a clinically relevant pathogen identified through conventional testing, but not through NGS cfDNA and 2 cases had antimicrobial resistance on culture, which is not detected by NGS cfDNA. CONCLUSION: While we did not find a specific clinical profile for NGS cfDNA use, positive results were essential to the diagnosis in 18% of cases with otherwise negative laboratory evaluation for the pathogen identified in NGS cfDNA. Negative tests affected the POC in 26% of cases by avoiding unnecessary antimicrobials in high risk immunocompromised patients and patients that presented with low-risk of infection, but unclear disease process. Caution must be exercised with reliance on this test with respect to antimicrobial resistance and risk of false negative results. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2021-12-04 /pmc/articles/PMC8644926/ http://dx.doi.org/10.1093/ofid/ofab466.864 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Abstracts
Quick, Rachel Downey
Martinez, Kelli A
Russo, Susan M
McGwier, Sarah E
Quirt, Rachel A
Hauger, Sarmistha Bhaduri
Fernandez, Mariosl
Murphey, Donald
667. Next Generation Sequencing of Microbial Cell Free DNA in the Diagnosis and Treatment of Infectious Disease in Children: When Does the Result Justify the Cost?
title 667. Next Generation Sequencing of Microbial Cell Free DNA in the Diagnosis and Treatment of Infectious Disease in Children: When Does the Result Justify the Cost?
title_full 667. Next Generation Sequencing of Microbial Cell Free DNA in the Diagnosis and Treatment of Infectious Disease in Children: When Does the Result Justify the Cost?
title_fullStr 667. Next Generation Sequencing of Microbial Cell Free DNA in the Diagnosis and Treatment of Infectious Disease in Children: When Does the Result Justify the Cost?
title_full_unstemmed 667. Next Generation Sequencing of Microbial Cell Free DNA in the Diagnosis and Treatment of Infectious Disease in Children: When Does the Result Justify the Cost?
title_short 667. Next Generation Sequencing of Microbial Cell Free DNA in the Diagnosis and Treatment of Infectious Disease in Children: When Does the Result Justify the Cost?
title_sort 667. next generation sequencing of microbial cell free dna in the diagnosis and treatment of infectious disease in children: when does the result justify the cost?
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644926/
http://dx.doi.org/10.1093/ofid/ofab466.864
work_keys_str_mv AT quickracheldowney 667nextgenerationsequencingofmicrobialcellfreednainthediagnosisandtreatmentofinfectiousdiseaseinchildrenwhendoestheresultjustifythecost
AT martinezkellia 667nextgenerationsequencingofmicrobialcellfreednainthediagnosisandtreatmentofinfectiousdiseaseinchildrenwhendoestheresultjustifythecost
AT russosusanm 667nextgenerationsequencingofmicrobialcellfreednainthediagnosisandtreatmentofinfectiousdiseaseinchildrenwhendoestheresultjustifythecost
AT mcgwiersarahe 667nextgenerationsequencingofmicrobialcellfreednainthediagnosisandtreatmentofinfectiousdiseaseinchildrenwhendoestheresultjustifythecost
AT quirtrachela 667nextgenerationsequencingofmicrobialcellfreednainthediagnosisandtreatmentofinfectiousdiseaseinchildrenwhendoestheresultjustifythecost
AT haugersarmisthabhaduri 667nextgenerationsequencingofmicrobialcellfreednainthediagnosisandtreatmentofinfectiousdiseaseinchildrenwhendoestheresultjustifythecost
AT fernandezmariosl 667nextgenerationsequencingofmicrobialcellfreednainthediagnosisandtreatmentofinfectiousdiseaseinchildrenwhendoestheresultjustifythecost
AT murpheydonald 667nextgenerationsequencingofmicrobialcellfreednainthediagnosisandtreatmentofinfectiousdiseaseinchildrenwhendoestheresultjustifythecost